Related Experiment Video

Updated: Jan 19, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.6K

SPTLC1 inhibits cell growth via modulating Akt/FOXO1 pathway in renal cell carcinoma cells

Zhenzhen Kong1, Xinming Guo2, Zhijian Zhao1

  • 1Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, China.

Biochemical and Biophysical Research Communications
|September 27, 2019
PubMed

Insights

Serine palmitoyltransferase long chain-1 (SPTLC1) is downregulated in renal cell carcinoma (RCC), and its restoration inhibits tumor growth by modulating the Akt/FOXO1 pathway, offering a new therapeutic target for RCC.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Sphingolipids are crucial for cell function.
  • Serine palmitoyltransferase long chain-1 (SPTLC1) is the rate-limiting enzyme in sphingolipid biosynthesis.
  • SPTLC1's role in renal cell carcinoma (RCC) is currently unknown.

Purpose of the Study:

  • To investigate the role of SPTLC1 in RCC.
  • To determine the association between SPTLC1 expression and patient survival.
  • To explore the mechanism by which SPTLC1 affects RCC growth.

Main Methods:

  • Analysis of SPTLC1 expression in RCC tissues and non-tumor tissues.
  • Correlation analysis between SPTLC1 expression and overall survival.
  • In vitro and in vivo experiments involving forced expression of SPTLC1.
  • Investigation of the Akt/FOXO1 signaling pathway.

Main Results:

  • SPTLC1 expression was significantly decreased in RCC tissues compared to non-tumor tissues.
  • Low SPTLC1 expression correlated with poorer overall survival in RCC patients.
  • Forced expression of SPTLC1 inhibited RCC cell growth in vitro and in vivo.
  • SPTLC1 modulated the Akt/FOXO1 signaling pathway.

Conclusions:

  • SPTLC1 plays a significant role in the regulation of RCC tumor growth.
  • Reduced SPTLC1 expression is a potential biomarker for poor prognosis in RCC.
  • Targeting SPTLC1 may represent a novel therapeutic strategy for RCC.
Keywords:
Akt/FOXO1 pathwayCell growthRenal cell carcinomaSPTLC1

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K